Status:
TERMINATED
Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF
Lead Sponsor:
Peking Union Medical College Hospital
Collaborating Sponsors:
Beijing Bethune public welfare fund
Conditions:
Uveitis
Macular Edema
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
As a primary exploratory study, this study aims to evaluate the short-term effectiveness of intravitreal Conbercept injection in UME, and to explore the correlation between inflammatory factors like V...
Detailed Description
Uveitic macular edema (UME) is one of the commonest and severest complications of chronic uveitis, and is also one of the important causes of permanent vision loss in uveitis. The pathophysiological m...
Eligibility Criteria
Inclusion
- age \>= 18 years old
- competent in signing the informed consent
- no severe systemic diseases unrelated to uveitis
- fulfill the criteria of refractory UME
Exclusion
- pregnant or preparing pregnancy
- already in other clinical trials
- blood pressure \>= 180/110mmHg
- BCVA of the contralateral eye \<= 20/200
- cardiovascular events within 3 months
Key Trial Info
Start Date :
October 12 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 12 2022
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04296838
Start Date
October 12 2019
End Date
February 12 2022
Last Update
October 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital (PUMCH)
Beijing, Beijing Municipality, China, 100730